Category Archives: Ataxia Treatment

Clinical Applications of Next-Gen Sequencing Debut at AGBT

By Julia Karow Next-gen sequencing for clinical applications and medical research were big themes at this year's Advances in Genome Biology and Technology meeting in Marco Island, Fla., reflecting the technology's continued move into medicine over the last year. Three conference sessions had a medical theme this year, focusing on the clinical translation of genomics, medical sequencing and genetic variation, and cancer and transcriptomes Continue reading →

Posted in Ataxia Treatment | Tagged analysis, boston, children, development, genome, health, illumina, kansas, management, medicine, national, spring, study, technology | Comments Off

Repligen Reports Preliminary Financial Results for the Quarter and Nine-Month Fiscal Period Ended December 31, 2011

WALTHAM, Mass.–(BUSINESS WIRE)– Repligen Corporation (NASDAQ:RGEN – News) today reported preliminary financial results for the quarter and nine-month fiscal period ended December 31, 2011. These results reflect significant accomplishments of the Company during the period, highlighted by the completion of our acquisition of Novozymes Biopharma Sweden AB on December 20, 2011 and the successful filing of the Company’s first new drug application (NDA) for SecreFlo™ on December 21, 2011. Continue reading →

Posted in Ataxia Treatment | Tagged ability, audio, business-, europe, markets-, nine, post, president, press-release-, repligen, securities, study, sweden | Comments Off

Embargoed news for Annals of Internal Medicine

Public release date: 20-Feb-2012 [ | E-mail | Share ] Contact: Abbey Anderson aanderson@acponline.org 215-351-2656 American College of Physicians 1. Death Rates from Viral Hepatitis Infections Steadily Increase From 1999 – 2007, Now Surpass HIV-related Deaths in U.S. Middle-aged Americans Disproportionately Affected by “Silent Epidemic” Approximately 3.2 million people in the United States are infected with chronic hepatitis C virus (HCV), a leading cause of liver disease, cirrhosis, and death. Continue reading →

Posted in Ataxia Treatment | Tagged a-leading-cause, a-third-article, assessment, prevention, silent-epidemic, then-the-burden, united, united-kingdom, usual | Comments Off

U.S. FDA accepts Pfizer's tafamidis NDA for treatment of TTR-FAP

Published on February 16, 2012 at 12:43 AM Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tafamidis meglumine, the company's investigational, novel, oral therapy for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) Continue reading →

Posted in Ataxia Treatment | Tagged constipation, medical, pfizer-inc-, pharmaceutical, today-announced, transthyretin, treatment, weight-loss | Comments Off

Intellect Neurosciences Submits Statement Setting Grounds for Appeal in European Patent Proceedings

NEW YORK, Feb. 14, 2012 /PRNewswire/ – Intellect Neurosciences, Inc. Continue reading →

Posted in Ataxia Treatment | Tagged a-amyloid-and, a-tau-protein, european, european-patent, intellect, likelihood, neurosciences, office, opposition, related-macular, report-on-form, research-, securities, united-states, york | Comments Off

Father in the fight of his life

EVERY single simple second of parenthood is precious for first-time father Marcus Purdue. Continue reading →

Posted in Ataxia Treatment | Tagged every, first-time-father, marcus, marcus-purdue-, precious-for, single-simple | Comments Off

ViroPharma Provides Update on Industrial Scale Supplement for Cinryze® (C1 Esterase Inhibitor [Human])

EXTON, Pa., Feb. 7, 2012 /PRNewswire/ — ViroPharma Incorporated (Nasdaq: VPHM – News) today announced the U.S Food and Drug Administration (FDA) issued a complete response letter regarding Cinryze® (C1 Esterase … Continue reading →

Posted in Ataxia Treatment | Tagged a-complete-response, cinryze-, complete-response, esterase, exton, fda, incorporated, letter-regarding, pharma-incorporated, today-announced, vphm | Comments Off

Intellect Neurosciences Files New Patent Applications for Immunotherapy Methods to Target Abnormal Tau Protein in …

NEW YORK, Feb. 7, 2012 /PRNewswire/ – Intellect Neurosciences, Inc. (OTCBB:ILNS.PK – News), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases today announced it has filed two United States and one international patent application regarding passive and active immunotherapy approaches targeting abnormal forms of tau protein that lead to death of nerve cells in Alzheimer's disease. Continue reading →

Posted in Ataxia Treatment | Tagged alzheimer, harvard-medical, intellect, pathological, quarterly, securities, united, york | Comments Off

LSU Veterinary Teaching Hospital offers acupuncture

One of the realities of veterinary medicine is that not all patients can be saved and not all can be kept comfortable as they come naturally to the end of their days. But a growing number of veterinarians are realizing that sometimes there are non-traditional therapies that can help animals have a better quality of life. Continue reading →

Posted in Ataxia Treatment | Tagged a-gift-from, a-growing-number, all-patients, are-realizing, days, private-donor, saved-and, their-days-, there-are | Comments Off

Foundation for Mitochondrial Medicine Awards Grant to Netherlands Research

ATLANTA, Feb. 7, 2012 (GLOBE NEWSWIRE) — The Foundation for Mitochondrial Research, a US-based non-profit dedicated to funding research for the treatment of mitochondrial disease, has awarded a $50,000 grant to Professor Jan Smeitink of the Netherlands for his research involving the development of new small molecule compounds to treat mitochondrial dysfunction Continue reading →

Posted in Ataxia Treatment | Tagged advanced-brain, development, georgia-, information, mitochondrial, professor, radboud, research-, the-development | Comments Off